Clinical Trials Directory

Trials / Terminated

TerminatedNCT05391633

Maternal Voice and Quantitative EEG (qEEG)

Effect of Recorded Maternal Voice on Quantitative EEG (qEEG) as a Marker for Developmental Risk in the Preterm Newborn

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
14 (actual)
Sponsor
University of New Mexico · Academic / Other
Sex
All
Age
28 Weeks – 33 Weeks
Healthy volunteers
Not accepted

Summary

A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.

Detailed description

This will be a randomized placebo-controlled clinical trial. Infants consented to participate will be randomized into the intervention arm or non-intervention arm by sealed unmarked envelope. All consented participants will have an initial EEG of 60-90 minutes duration, performed at 32 5/7 - 32 6/7 weeks (and after 72 hours of life). Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), eligible subjects will proceed with randomized intervention or placebo for a 2-week (14 day) intervention period. All infants will receive a 2nd EEG of 30-60 minutes duration, performed between 35 0/7 - 35 6/7 weeks corrected gestational age, following completion of either the intervention or non-intervention arm (with the goal of the 2nd EEG occurring within 48 hours of infants having completed the intervention vs. non-intervention arm). EEG technician and all persons reviewing, pruning and analyzing data from the qEEG will be blinded to whether the infant was in the intervention or the non-intervention arm.

Conditions

Interventions

TypeNameDescription
BEHAVIORALRecorded Maternal Voice60-minute looped recording of maternal voice, played once daily for 14 total days.
BEHAVIORALPlacebo Recording60-minute blank recording played once daily for 14 total days.

Timeline

Start date
2022-02-15
Primary completion
2024-06-12
Completion
2024-06-12
First posted
2022-05-26
Last updated
2025-09-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05391633. Inclusion in this directory is not an endorsement.